Amedisys Gets a Buy Rating from Oppenheimer

By Carrie Williams

Oppenheimer analyst Michael Wiederhorn assigned a Buy rating to Amedisys (NASDAQ: AMED) today and set a price target of $60. The company’s shares closed yesterday at $52.78.

Wiederhorn commented:

“We attended meetings with the management team of Amedisys and believe the business itself is performing well. Although there is a major overhang from the Medicare proposal for 2019, we are taking a constructive view that improvements of some magnitude will be made, with the upside potential that the rule is scrapped in its entirety.”

According to, Wiederhorn is a top 100 analyst with an average return of 16.1% and a 70.1% success rate. Wiederhorn covers the Services sector, focusing on stocks such as Cross Country Healthcare, Addus Homecare Corp, and Envision Healthcare.

Currently, the analyst consensus on Amedisys is Moderate Buy and the average price target is $55.17, representing a 4.5% upside.

In a report issued on September 5, Jefferies also reiterated a Buy rating on the stock with a $60 price target.

The company has a one year high of $65.91 and a one year low of $34.58. Currently, Amedisys has an average volume of 392.2K.

Based on the recent corporate insider activity of 43 insiders, corporate insider sentiment is neutral on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Amedisys, Inc. provides hospice and home health care services to the chronic, co-morbid and aging American population. The company focuses on delivering patient-centered care, whether that is home-based recovery and rehabilitation after an operation or injury, care focused on empowering them to manage a chronic disease, palliative care for those with a terminal illness, or hospice care at the end of life. It operates its business through the following business segments: Home Health and Hospice. The Home Health segment delivers services in the homes of individuals who may be recovering from an illness, injury or surgery. The Hospice segment provides care that is designed to provide comfort and support for those who are facing a terminal illness. Amedisys was founded by William F. Borne in 1982 and is headquartered in Baton Rouge, LA.